National bill seeks to jump‐start psychedelic treatment for veterans
Alcoholism & Drug Abuse Weekly July 11, 2026 DOI: 10.1002/adaw.34973 via OpenAlex
Summary
AI-generated from the abstractA U.S. House member from Arizona introduced a bill requiring the Pentagon to report on emerging evidence that psychedelic drugs may benefit military veterans with treatment-resistant post-traumatic stress disorder (PTSD). The legislation, sponsored by Republican Rep. Abe Hamadeh, followed his visit to a nonprofit research lab in Arizona conducting the first federally approved clinical trial using organic psilocybin-containing mushrooms as a potential treatment for PTSD in veterans and first responders.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Keywords | Legislation Pentagon Posttraumatic stress Clinical trial House of representatives |
| Key finding | Legislation was introduced requiring the Pentagon to report on evidence that psychedelic drugs may benefit veterans with treatment-resistant PTSD. |
Abstract
A U.S. House member from Arizona has introduced legislation that would require the Pentagon to report on emerging evidence which suggests that psychedelic drugs can benefit military veterans with treatment‐resistant post‐traumatic stress disorder (PTSD). Republican Rep. Abe Hamadeh introduced the bill after visiting a nonprofit research lab in Arizona that is conducting the first federally approved clinical trial using organic psilocybin‐containing mushrooms as a potential treatment for PTSD in veterans and first responders.